ARROWHEAD PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Accumulated Other Comprehensive Income of -$1.23 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.23M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $742.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $6.70M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $6.44M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$1.23M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $742.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $6.70M 10-Q · filed 2026-02-05 | |
| 2025-09-30 | $6.44M 10-Q · filed 2026-08-04 | |
| 2025-06-30 | $5.36M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $4.39M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $4.14M 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $4.75M 10-K · filed 2025-11-25 | |
| 2024-06-30 | -$987.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$1.09M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$1.25M 10-Q · filed 2024-02-06 | |
| 2023-09-30 | -$3.22M 10-K · filed 2024-11-26 | |
| 2023-06-30 | -$411.00K 10-Q · filed 2023-08-07 | |
| 2023-03-31 | -$332.00K 10-Q · filed 2023-05-02 | |
| 2022-12-31 | -$258.00K 10-Q · filed 2023-02-06 | |
| 2022-09-30 | -$136.00K 10-K · filed 2023-11-29 | |
| 2022-06-30 | -$140.00K 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$107.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$108.00K 10-Q · filed 2022-02-02 | |
| 2021-09-30 | -$69.00K 10-K · filed 2022-11-28 | |
| 2021-06-30 | $62.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $102.00K 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $198.00K 10-Q · filed 2021-02-04 | |
| 2020-09-30 | $18.00K 10-K · filed 2021-11-22 | $18.43K 10-K · filed 2020-11-23 |
| 2020-06-30 | -$175.22K 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$629.11K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$195.55K 10-Q · filed 2020-02-05 | |
| 2019-09-30 | -$391.62K 10-K · filed 2020-11-23 | |
| 2019-06-30 | -$103.08K 10-Q · filed 2019-08-05 | |
| 2019-03-31 | -$71.91K 10-Q · filed 2019-05-08 | |
| 2018-12-31 | -$43.74K 10-Q · filed 2019-02-07 | |
| 2018-09-30 | -$21.56K 10-K · filed 2019-11-25 | |
| 2018-06-30 | -$3.34K 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $25.27K 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $23.70K 10-Q · filed 2018-02-09 | |
| 2017-09-30 | $33.23K 10-K · filed 2018-12-11 | |
| 2017-06-30 | -$18.39K 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$30.70K 10-Q · filed 2017-05-03 | |
| 2016-12-31 | -$185.16K 10-Q · filed 2017-02-06 | |
| 2016-09-30 | $7.45K 10-K · filed 2017-12-12 | |
| 2016-06-30 | -$30.71K 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $59.91K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$90.61K 10-Q · filed 2016-02-09 | |
| 2015-09-30 | -$136.43K 10-K · filed 2016-12-14 | |
| 2015-06-30 | -$65.95K 10-Q · filed 2015-08-04 | |
| 2015-03-31 | -$63.97K 10-Q · filed 2015-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |